EURETINA 2024: Cardio-ocular syndrome and retinal microvasculature changes in acute heart failure

News
Article

The research team used spectral-domain OCT and OCT angiography imaging to study the changes in the retinal microvasculature in patients

A human heart paired with a digital display of an echocardiogram. Image credit: ©Sergey Nivens – stock.adobe.com

The study could support the use of OCTA in the assessment of patients with acute heart failure. Image credit: ©Sergey Nivens – stock.adobe.com

Alaa Din Abdin, MD, and colleagues reported that a “remarkable” reversible change occurred in the retinal microvessels after patients experienced acute decompensated heart failure (ADHF). He is a consultant ophthalmologist, vitreoretinal surgeon, from Saarland University Medical Center, Homburg, Germany. The investigators reported their findings at the 24th Euretina Congress in Barcelona.

The research team used spectral-domain optical coherence tomography (SD-OCT) and OCT angiography (OCTA) imaging to study the changes in the retinal microvasculature in patients admitted to a university medical center during ADHF and then after recompensation. The findings were compared to those of age-matched controls who had no known cardiac or retinal disease.

The patients included in the study, who were all adults, had been hospitalised with the ADHF diagnosis, regardless of the left ventricular ejection fraction (LVEF); all had been treated with a minimal dose of 40 mg of intravenous furosemide or equivalent. All patients underwent transthoracic echocardiography, and ocular examinations that included measurement of the best-corrected visual acuity (VA), dilated funduscopy, SD-OCT and OCTA during the first 24 hours in the hospital and after recompensation before discharge. The control group was comprised of 40 participants without documented cardiac or retinal diseases.

Retinal effects of ADHF

The study ran a 1-year course from August 2022 to August 2023. Forty patients with ADHF (mean age, 78.9 ± 8.76 years; 32% female) were included. The mean LVEF was 43 ± 12.8%. All patients were treated with intravenous diuretics (median, 4.3± 2.8 days). The N-terminal pro-B-type natriuretic peptide level, a factor used to diagnose heart failure, decreased significantly between baseline and discharge from 10,396 pg/ml (interquartile range [IQR], 6,410 pg/ml) and 6,380 pg/ml (IQR, 3,933 pg/ml, respectively (p<0.001), as did the diameters of the inferior vena cava from 2.13± 0.4 cm to 1.63 ± 0.3 cm, respectively (p=0.003).

The investigators found that the patients had impaired VA at admission compared with the control group (0.15±0.1 vs. 0.35± 0.1, respectively (p<0.001), reduced macular vessel density (18.0 ± 1.9 mm/mm2 vs. 14.3± 3.6 mm/mm2, respectively (p <0.001) and perfusion density (42.6± 3.2% vs. 35.2± 9.7%, respectively) (p <0.001).

In contrast, after recompensation, the mean overall vessel density and mean overall perfusion density increased markedly at the time of discharge (14.3± 3.6 vs. 19.7± 2.6, p=0.001; and 35.2± 9.7 vs. 39.2± 6.5, respectively (p=0.005). The mean diameter of the superior temporal retinal vein at admission was significantly larger compared to the control group (136 ± 19 μm vs. 124 ± 22 μm, respectively (p=0.008) and decreased significantly to 122 ± 15 μm at discharge (p<0.001).

The authors concluded, “This analysis revealed a remarkable reversible change in retinal microvessels after ADHF. This may provide valuable evidence for the use of OCTA in the assessment of overall microperfusion and hemodynamic status in patients with acute heart failure."

Reference

Abdin AD, Amr Abdin A, Aljundi W, et al. Cardio-ocular syndrome: Retinal microvasculature changes in acute heart failure. Presented at the 24th Euretina Congress, September 19-22, Barcelona, Spain. Session: Speaker’s Corner: Diabetes & Vascular Diseases, September 19, 2024.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
Related Content
© 2025 MJH Life Sciences

All rights reserved.